EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial

Gerard M Walls, Hitesh Mistry, Fabrice Barlesi, Andrea Bezjak, Cecile Le Pechoux, Mary O'Brien, Jan P Van Meerbeeck, Fiona Blackhall, Corinne Faivre-Finn

International Journal of Radiation Oncology*Biology*Physics · 2024-08 · 119 (5) · 1386-1390

DOI: 10.1016/j.ijrobp.2024.02.063 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-08. Verfasst von Gerard M Walls und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Patrick G. Johnston Centre for Cancer Res…. Hauptthemen laut MEDLINE: Lung Neoplasms, Chemoradiotherapy, Small Cell Lung Carcinoma, Etoposide. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered with conformal techniques. METHODS AND MATERIALS: CONVERT (NCT00433563) randomized patients 1:1 between OD RT (66 Gy/33 fractions/6.5 weeks) and BD RT (45 Gy/30 fractions/3 weeks), both delivered with concurrent cisplatin/etoposide. Three-dimensional conformal RT was mandatory, intensity-modulated RT was permitted, and elective nodal irradiation was not allowed. Prophylactic cranial irradiation was delivered at the discretion of treating clinicians. RT treatment planning was subject to central quality assurance. RESULTS: Five hundred forty-seven patients were recruited at 73 centers. The median follow-up for the surviving cohort (n = 164) was 81.2 months. The median survival for the OD and BD arms were 25.4 months (95% CI, 21.1-30.9) and 30.0 months (95% CI, 25.3-36.5; hazard ratio, 1.13; 95% CI, 0.92-1.38; P = .247). Performance status and tumor volume were associated with survival on multivariate analysis. No treatment-related deaths occurred subsequent to the initial analysis performed in 2017. Regarding late toxicity, 7 patients in the OD arm developed grade 3 esophagitis, 4 of which went on to develop stricture or fistulation, compared with no patients in the BD arm. Grade 3 pulmonary fibrosis occurred in 2 and 3 patients in the OD and BD arms, respectively. CONCLUSIONS: As the CONVERT trial did not demonstrate the superiority of OD RT and this regimen had a slightly worse toxicity profile after 80 months of follow-up, 45 Gy BD should remain the standard of care in limited stage small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsChemoradiotherapySmall Cell Lung CarcinomaEtoposideCisplatinRadiotherapy, ConformalHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsDose Fractionation, RadiationTreatment OutcomeRadiotherapy, Intensity-ModulatedAdultTime FactorsCranial Irradiation

Substanzen

EtoposideCisplatin

Autor:innen und Institutionen

  • Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom. Electronic…
  • Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
  • Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Paris Saclay University, Medical Oncology Department, Gustave Rous…
  • Canadian Cancer Trials Group, Princess Margaret Cancer Center, Toronto, Canada.
  • Radiation Oncology Department, Gustave Roussy, Villejuif, France.
  • Department of Medicine, Royal Marsden NHS Foundation Trust, Surrey, United Kingdom.

Zitieren

APA

Walls, G. M., Mistry, H., Barlesi, F., Bezjak, A., Pechoux, C. L., O'Brien, M., Van Meerbeeck, J. P., Blackhall, F., & Faivre-Finn, C. (2024). Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. International Journal of Radiation Oncology*Biology*Physics, 119(5), 1386-1390. https://doi.org/10.1016/j.ijrobp.2024.02.063

Vancouver

Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O'Brien M, et al. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. International Journal of Radiation Oncology*Biology*Physics. 2024;119(5):1386-1390. doi:10.1016/j.ijrobp.2024.02.063

BibTeX
@article{Walls2024,
  author = {Walls, Gerard M and Mistry, Hitesh and Barlesi, Fabrice and Bezjak, Andrea and Pechoux, Cecile Le and O'Brien, Mary and Van Meerbeeck, Jan P and Blackhall, Fiona and Faivre-Finn, Corinne},
  title = {Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  volume = {119},
  number = {5},
  pages = {1386--1390},
  doi = {10.1016/j.ijrobp.2024.02.063}
}
Kostenlos starten →